Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 0.73 |
| ▸ | GIPR | P48546 | 12/20 | 0.70 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.70 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.70 |
| ▸ | DUSP2 | Q05923 | 1/20 | 0.70 |
| ▸ | GLP1R | P43220 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660348 | 1.00 | GCGR (0.73) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL3251746 | 0.91 | GCGR (0.61) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL3252496 | 0.90 | GCGR (0.61) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2644824 | 0.88 | GCGR (0.77) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL11947944 | 0.85 | GCGR (0.67) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2645262 | 0.83 | GCGR (0.75) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2657768 | 0.83 | GCGR (0.75) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2662877 | 0.83 | GCGR (0.52) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| Mk-0893 SCHEMBL675777 | 0.83 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL13644751 | 0.83 | GCGR (0.88) | GCGRGIPRVIPR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799818-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799818-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799818-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7598285-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598285-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598285-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| EP-1756064-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | GCGR 188/4885GIPR 205/4885VIPR2 1017/4885 |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | GOT2, GOT1, IAPP | GCGR 189/4885GIPR 177/4885VIPR2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.